Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment
| العنوان: | Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment |
|---|---|
| المؤلفون: | Uwe Maskos, Sylvia Lombardo |
| المساهمون: | Neurobiologie intégrative des Systèmes cholinergiques (NISC), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), SL was supported by EU FP7 'BRAINTRAIN', Fondation pour la Recherche Médicale FRMand Institut Pasteur programme 'PasteurInnov' 2012, European Project: 238055,EC:FP7:PEOPLE,FP7-PEOPLE-ITN-2008,BRAINTRAIN(2009), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS) |
| المصدر: | Neuropharmacology Neuropharmacology, 2015, The Nicotinic Acetylcholine Receptor: From Molecular Biology to Cognition, 96 (Pt B), pp.255-62. ⟨10.1016/j.neuropharm.2014.11.018⟩ Neuropharmacology, Elsevier, 2015, The Nicotinic Acetylcholine Receptor: From Molecular Biology to Cognition, 96 (Pt B), pp.255-62. ⟨10.1016/j.neuropharm.2014.11.018⟩ |
| بيانات النشر: | HAL CCSD, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Pathology, medicine.medical_specialty, Nicotine, Mice, Transgenic, Receptors, Nicotinic, Cellular and Molecular Neuroscience, Alzheimer Disease, mental disorders, Muscarinic acetylcholine receptor, medicine, Muscarinic acetylcholine receptor M4, Animals, Humans, Nicotinic Agonists, Pharmacology, Neurons, Amyloid beta-Peptides, Muscarinic acetylcholine receptor M3, Brain, medicine.disease, Receptors, Muscarinic, 3. Good health, Nicotinic acetylcholine receptor, Disease Models, Animal, Nicotinic agonist, Cholinergic, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Alzheimer's disease, Psychology, Neuroscience, Acetylcholine, medicine.drug |
| الوصف: | International audience; Alzheimer's Disease (AD) is the major form of senile dementia, characterized by neuronal loss, extracellular deposits, and neurofibrillary tangles. It is accompanied by a loss of cholinergic tone, and acetylcholine (ACh) levels in the brain, which were hypothesized to be responsible for the cognitive decline observed in AD. Current medication is restricted to enhancing cholinergic signalling for symptomatic treatment of AD patients. The nicotinic acetylcholine receptor family (nAChR) and the muscarinic acetylcholine receptor family (mAChR) are the target of ACh in the brain. Both families of receptors are affected in AD. It was demonstrated that amyloid beta (Aβ) interacts with nAChRs. Here we discuss how Aβ activates or inhibits nAChRs, and how this interaction contributes to AD pathology. We will discuss the potential role of nAChRs as therapeutic targets. This article is part of the Special Issue entitled 'The Nicotinic Acetylcholine Receptor: From Molecular Biology to Cognition'. |
| اللغة: | English |
| تدمد: | 0028-3908 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab51442e164f28cd059825162b2fe1f3Test https://hal-pasteur.archives-ouvertes.fr/pasteur-01197130/documentTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....ab51442e164f28cd059825162b2fe1f3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00283908 |
|---|